Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada

OBJECTIVE: Liraglutide 3.0 mg is associated with clinically significant weight loss in clinical trials, but real‐world data are lacking. In this analysis, weight loss and persistence outcomes with liraglutide 3.0 mg were assessed across obesity classes, in a real‐world clinical setting. METHODS: Sec...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Obes Sci Pract
Egile Nagusiak: Wharton, Sean, Haase, Christiane L., Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca A. G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Short Communications
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7448201/
https://ncbi.nlm.nih.gov/pubmed/32874678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/osp4.420
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak